Clinical trials: Vascular Inflammation
Embolism and Thrombosis, Cardiovascular
Collection of Blood Samples for New Diagnostic Devices 2
To research and develop new state of the art diagnostic biomarkers on the LumiraDx Platform that are comparable to the approved gold standard reference methods and will radically enhance clinicians and patients ability to monitor…
- Conditions
- Embolism and Thrombosis, Cardiovascular, Renal, Inflammation
- Trial name
- NOVEL-2 (NCT05568966)
- Testing
- Venous blood draw, Fingerstick
- Where
- 7 sites in United Kingdom
- Volunteers
- 20,000 people
- Sponsor
- LumiraDx UK Limited
Coronary Artery Disease
Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease
The primary purpose of this study is to assess the safety and tolerability of E5555 in subjects with coronary artery disease.
- Trial name
- NCT00312052
- Testing
- E5555
- Where
- 2 sites in United States
- Volunteers
- 720 people
- Sponsor
- Eisai Inc.
Peripheral Arterial Disease, Arterial Occlusive Diseases
SIMPADICO - Study of Immune Modulation Therapy in Peripheral Arterial Disease and Intermittent Claudication Outcomes
The purpose of this study is to assess the effects of the Celacade™ system in patients with intermittent claudication.
- Conditions
- Peripheral Arterial Disease, Arterial Occlusive Diseases, Intermittent Claudication
- Trial name
- NCT00111826
- Testing
- Celacade™ system
- Volunteers
- 500 people
- Sponsor
- Vasogen
Coronary Stenosis, Periodontal Diseases
Periodontal Disease, Inflammation and Acute Coronary Syndromes
Recent studies have shown that the systemic inflammation caused by periodontal disease (PD) can determine important changes in the coronary arteries, favoring atherosclerosis progression and development of acute coronary…
- Conditions
- Coronary Stenosis, Periodontal Diseases, Acute Coronary Syndrome, Non-ST Elevation Myocardial Infarction
- Trial name
- ATHERODENT (NCT03395041)
- Testing
- cardiac imaging tests
- Where
- Romania
- Volunteers
- 149 people
- Sponsor
- Cardio Med Medical Center
Sepsis, Venous Thromboembolism
An Observational Study in the United States to Learn How Venous Thromboembolism, Disseminated Intravascular Coagulation, and Sepsis Are Related
This is an observational study in which data already collected from people with venous thromboembolism (VTE) due to sepsis (blood poisoning) are studied.
- Conditions
- Sepsis, Venous Thromboembolism, Disseminated Intravascular Coagulation
- Trial name
- NCT06765681
- Testing
- Diagnosis of both VTE and sepsis
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Bayer
Bacterial Infections, Gram-Positive Bacterial Infections
Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria
This study will treat patients who have a short term central catheter that is thought to be infected with a specific bacteria (gram positive bacteria)
- Conditions
- Bacterial Infections, Gram-Positive Bacterial Infections, Bacteremia
- Trial name
- NCT00037050
- Testing
- Linezolid, Vancomycin, Oxacillin
- Volunteers
- 739 people
- Sponsor
- Pfizer
Coronary Artery Disease, Systemic Inflammatory Response
CCTA Coronary Hemodynamics, Systemic Inflammation and Vulnerable Plaques (COHESIVE)
Although there are numerous studies that have demonstrated the impact of systemic inflammation on coronary plaque vulnerability, there are few literature data regarding the influence of coronary plaque localization within the…
- Conditions
- Coronary Artery Disease, Systemic Inflammatory Response, Chronic Coronary Syndrome, Atherosclerosis
- Trial name
- COHESIVE (NCT05488249)
- Testing
- Cardiac imaging tests, Venous blood sample collection
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Cardio Med Medical Center
Embolism and Thrombosis, Infection
Evaluation of the LumiraDx Point of Care D-Dimer and CRP Tests
A Multicenter Study Conducted to Evaluate the Agreement between Fingerstick Whole Blood, Venous Whole Blood and Plasma Determined on the LumiraDx Point of Care D-Dimer and Point of Care CRP Tests to Results on the Reference…
- Conditions
- Embolism and Thrombosis, Infection, Inflammation
- Trial name
- NOVEL-3 (NCT04375982)
- Testing
- Venepuncture, Fingerstick
- Where
- 4 sites in United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- LumiraDx UK Limited
Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis
Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,
This was a multi-center, randomized, active-controlled, open-label study. Approximately 24 patients with active, non-infectious intermediate-, posterior-, or panuveitis requiring systemic immunosuppressive therapy were enrolled.
- Conditions
- Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Panuveitis
- Trial name
- NCT01526889
- Testing
- LFG316, Conventional Therapy
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Giant Cell Arteritis
A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis
This study was designed to evaluate the efficacy and safety of secukinumab compared to placebo to maintain disease remission up to 28 weeks including corticosteroid tapering, as well as up to 1 year (52 weeks) in patients with…
- Trial name
- TitAIN (NCT03765788)
- Testing
- Secukinumab 300 mg, s.c., Prednisolone
- Where
- 11 sites in Germany
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Sepsis and Coagulopathy
The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy
The purpose of the study is to evaluate if ART-123 given to patients who have severe sepsis can decrease mortality.
- Trial name
- Scarlet2 (NCT03517501)
- Testing
- ART-123
- Sponsor
- Asahi Kasei Pharma America Corporation
Hypertension, Coronary Arteriosclerosis
Inflammation and Coronary Artery Disease: Role of AT1-Receptor Antagonism
Effects of AT1 receptor antagonist telmisartan on the primary endpoint inflammatory parameters in patients with coronary artery disease (CAD). Secondary endpoints are alterations in clinical course and blood pressure
- Trial name
- NCT00274144
- Testing
- telmisartan 40 mg
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Boehringer Ingelheim
Venous Insufficiency, Venous Reflux
Effects of Non Contact Low Frequency Ultrasound in Healing Venous Leg Ulcers
This trial is a prospective, randomized, controlled, multi-center study of subjects presenting with chronic lower extremity venous ulcers.
- Conditions
- Venous Insufficiency, Venous Reflux, Lower Extremity Ulcer
- Trial name
- NCT01549860
- Testing
- MIST Therapy
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- Celleration, Inc.
Intraocular Inflammation, Suspected Endophthalmitis
A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022
Specific study objectives include: To describe patient and provider characteristics for aflibercept patients and aflibercept user injections by aflibercept dispensing device, overall, and stratified by time (quarterly, annually).
- Trial name
- NCT05791695
- Testing
- Non Applicable
- Where
- United States
- Volunteers
- 155,413 people
- Sponsor
- Regeneron Pharmaceuticals
Type 2 Diabetes
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EV-077 in Type 2 Diabetic Subjects
The principal objective of this study is to evaluate the safety and tolerability of repeated doses of EV-077-3201-2TBS given to diabetic subjects over a 4 week treatment period.
- Trial name
- NCT01551381
- Testing
- EV-077
- Where
- Germany
- Volunteers
- 33 people
- Sponsor
- Evolva SA
Peripheral Arterial Diseases
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
To assess the safety and effectiveness of adventitial deposition of the Study Drug in reducing inflammation and restenosis in patients with clinical evidence of claudication or critical limb ischemia and an angiographically…
- Trial name
- DANCE (NCT01983449)
- Testing
- Dexamethasone Sodium Phosphate Injection, USP
- Where
- 38 sites in United States
- Volunteers
- 285 people
- Sponsor
- Mercator MedSystems, Inc.
Coronary Artery Disease
Study Effect of VIA-2291 on Vascular Inflammation
This is a dose ranging study to compare the effect of VIA-2291 vs. Placebo on various inflammatory biomarkers in patients with recent acute coronary events
- Trial name
- NCT00358826
- Testing
- VIA-2291
- Where
- 12 sites in United States, Canada
- Volunteers
- 191 people
- Sponsor
- Tallikut Pharmaceuticals, Inc.
Hemorrhoids, Hemorrhoids, Internal
SCI-Pex Study - Safety and Performance of PexyEazy®, a Device for Treatment of Hemorrhoids
The SCI-Pex study is a multicenter, prospective, non-controlled investigation on PexyEazy®, a new device for treatment of hemorrhoids based on the mucopexy method.
- Conditions
- Hemorrhoids, Hemorrhoids, Internal, Suture; Complications, Infection or Inflammation, Rectal Diseases
- Trial name
- SCI-Pex (NCT05782010)
- Testing
- PexyEazy
- Where
- 3 sites in Sweden
- Volunteers
- 35 people
- Sponsor
- Developeration AB
Chronic Plaque Psoriasis
Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis
This study evaluated the effect of secukinumab compared to placebo on aortic vascular inflammation in adult patients who have moderate to severe plaque psoriasis that is poorly controlled by current psoriasis treatments.
- Trial name
- VIP-S (NCT02690701)
- Testing
- Secukinumab 300 mg
- Where
- 12 sites in United States
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
Primary Mitochondrial Disease
OMT-28 in Patients With Primary Mitochondrial Disease (PMD) (PMD-OPTION)
The goal of this clinical trial is to learn about the treatment effects of the investigational new drug OMT-28 in patients with Primary Mitochondrial Disease.
- Trial name
- PMD-OPTION (NCT05972954)
- Testing
- OMT-28
- Where
- 9 sites in Germany, Italy and 1 more
- Volunteers
- 28 people
- Sponsor
- Omeicos Therapeutics GmbH